📊 RCUS Key Takeaways
Is Arcus Biosciences, Inc. (RCUS) a Good Investment?
Arcus Biosciences exhibits exceptional 648.5% revenue growth indicating strong product adoption, but severe operational losses (-$386M) and negative operating cash flow (-$482M) create unsustainable cash burn. While the balance sheet provides near-term runway with $222M cash and low leverage, the company must achieve profitability or secure additional financing quickly as burn rate suggests limited viability without significant operational improvement.
Why Buy Arcus Biosciences, Inc. Stock? RCUS Key Strengths
- Exceptional revenue growth of 648.5% YoY signals strong commercial product momentum
- Excellent liquidity position with 4.36x current ratio and $222M cash reserves provides financial flexibility
- Low leverage (0.16x Debt/Equity) and moderate long-term debt ($99M) limits financial risk
RCUS Stock Risks: Arcus Biosciences, Inc. Investment Risks
- Severe operating cash flow burn of -$482M annually with negative FCF margin of -196%, indicating unsustainable cash consumption
- Large operating losses (-$386M) and net losses (-$353M) despite strong revenue growth, signaling fundamental profitability challenges
- Cash runway concerns: at current burn rate (~$482M annually), existing cash ($222M) covers less than 6 months of operations without profitability improvement
Key Metrics to Watch
- Gross margin trends and absolute gross profit dollars as revenue scales
- Operating cash flow trajectory and time to cash flow breakeven
- Cash balance and quarterly burn rate changes to assess runway adequacy
Arcus Biosciences, Inc. (RCUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.36x current ratio provides a solid financial cushion.
RCUS Profit Margin, ROE & Profitability Analysis
RCUS vs Healthcare Sector: How Arcus Biosciences, Inc. Compares
How Arcus Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arcus Biosciences, Inc. Stock Overvalued? RCUS Valuation Analysis 2026
Based on fundamental analysis, Arcus Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arcus Biosciences, Inc. Balance Sheet: RCUS Debt, Cash & Liquidity
RCUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arcus Biosciences, Inc.'s revenue has declined by 87% over the 5-year period, indicating business contraction. The most recent EPS of $-4.15 indicates the company is currently unprofitable.
RCUS Revenue Growth, EPS Growth & YoY Performance
RCUS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.0M | N/A | $-1.00 |
| Q2 2025 | $8.0M | N/A | $0.00 |
| Q1 2025 | $8.0M | -$4.0M | $-0.05 |
| Q3 2024 | $32.0M | -$4.0M | $-0.94 |
| Q2 2024 | $29.0M | -$4.0M | $-1.02 |
| Q1 2024 | $25.0M | -$4.0M | $-0.05 |
| Q3 2023 | $32.0M | -$65.0M | N/A |
| Q2 2023 | $27.0M | -$67.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arcus Biosciences, Inc. Dividends, Buybacks & Capital Allocation
RCUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arcus Biosciences, Inc. (CIK: 0001724521)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RCUS
What is the AI rating for RCUS?
Arcus Biosciences, Inc. (RCUS) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RCUS's key strengths?
Claude: Exceptional revenue growth of 648.5% YoY signals strong commercial product momentum. Excellent liquidity position with 4.36x current ratio and $222M cash reserves provides financial flexibility.
What are the risks of investing in RCUS?
Claude: Severe operating cash flow burn of -$482M annually with negative FCF margin of -196%, indicating unsustainable cash consumption. Large operating losses (-$386M) and net losses (-$353M) despite strong revenue growth, signaling fundamental profitability challenges.
What is RCUS's revenue and growth?
Arcus Biosciences, Inc. reported revenue of $247.0M.
Does RCUS pay dividends?
Arcus Biosciences, Inc. does not currently pay dividends.
Where can I find RCUS SEC filings?
Official SEC filings for Arcus Biosciences, Inc. (CIK: 0001724521) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RCUS's EPS?
Arcus Biosciences, Inc. has a diluted EPS of $-3.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RCUS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Arcus Biosciences, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RCUS stock overvalued or undervalued?
Valuation metrics for RCUS: ROE of -55.9% (sector avg: 15%), net margin of -142.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RCUS stock in 2026?
Our dual AI analysis gives Arcus Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RCUS's free cash flow?
Arcus Biosciences, Inc.'s operating cash flow is $-482.0M, with capital expenditures of $2.0M. FCF margin is -196.0%.
How does RCUS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -142.9% (avg: 12%), ROE -55.9% (avg: 15%), current ratio 4.36 (avg: 2).